Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)

被引：0
|
作者：
da Silva, I. Pires [1 ]
Zakria, D. [2 ]
Ahmed, T. [1 ]
Trojaniello, C. [3 ]
Dimitriou, F. [4 ]
Allayous, C. [5 ]
Gerard, C. [6 ]
Zimmer, L. [7 ]
Lo, S. [1 ]
Michielin, O. A. [6 ]
Lebbe, C. [8 ]
Mangana, J. [4 ]
Ascierto, P. A. [3 ]
Johnson, D. [2 ]
Carlino, M. [9 ]
Menzies, A. M. [10 ]
Long, G. V. [10 ]
机构：
[1] Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia
[2] Vanderbilt Univ, Med Ctr, Med Oncol, Nashville, TN USA
[3] IRCCS Fdn Pascale, Ist Nazl Tumori, Canc Immunotherapy & Dev Therapeut, Melanoma, Naples, Italy
[4] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
[5] Hop St Louis, AP HP, Dermatol, Paris, France
[6] CHU Vaudois CHUV, Oncol, Lausanne, Switzerland
[7] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[8] Hop St Louis, AP HP, Dermatol, Paris, France
[9] Univ Sydney, Melanoma Inst Australia, Westmead Blacktown Hosp, Wollstonecraft, NSW, Australia
[10] Univ Sydney, Melanoma Inst Australia, North Shore & Mater Hosp, Sydney, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042P
引用
收藏
页码：S873 / S874
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
    Pires da Silva, Ines
    Zakria, Danny
    Ahmed, Tasnia
    Trojanello, Claudia
    Dimitriou, Florentia
    Allayous, Clara
    Gerard, Camille
    Zimmer, Lisa
    Lo, Serigne
    Michielin, Olivier
    Lebbe, Celeste
    Mangana, Johanna
    Ascierto, Paolo Antonio
    Johnson, Douglas B.
    Carlino, Matteo
    Menzies, Alexander
    Long, Georgina
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [2] Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
    Da Silva, Ines Pires
    Ahmed, Tasnia
    Lo, Serigne
    Reijers, Irene L. M.
    Weppler, Alison
    Warner, Allison Betof
    Patrinely, James Randall
    Serra-Bellver, Patricio
    Lebbe, Celeste
    Mangana, Joanna
    Nguyen, Khang
    Zimmer, Lisa
    Ascierto, Paolo Antonio
    Stout, Dan
    Lyle, Megan
    Klein, Oliver
    Gerard, Camille Lea
    Blank, Christian U.
    Menzies, Alexander M.
    Long, Georgina V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Mechanisms of response to anti-PD1 (PD1) combined with Ipilimumab (IPI) in patients (pts) with PD1-resistant metastatic melanoma (MM)
    da Silva, Ines Pires
    Conway, Jordan
    Edwards, Jarem
    Marsh-Wakefield, Felix
    Quek, Camelia
    Ferguson, Angela
    Johnansson, Peter
    Carlino, Matteo
    Menzies, Alexander
    Wilmott, James
    Palendira, Umaimainthan
    Scolyer, Richard
    Long, Georgina
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [4] Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma
    Albrecht, L. J.
    Dimitriou, F.
    Grover, P.
    Hassel, J. C.
    Erdmann, M.
    Forschner, A.
    Johnson, D.
    Livingstone, E.
    Roesch, A.
    Ugurel, S.
    Schulz, C.
    Berking, C.
    Menzies, A. M.
    Long, G. V.
    Dummer, R.
    Schadendorf, D.
    Zimmer, L.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 44 - 44
  • [5] Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy
    Nahar, K. J.
    Rawson, R. V.
    Sandanayake, N.
    Tattersal, S.
    Carlino, M. S.
    Palendira, U.
    Scolyer, R. A.
    Long, G. V.
    Menzies, A. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 552 - 552
  • [6] Prognostic factors for efficacy of Ipilimumab used after anti-PD1 and/ or BRAF plus MEK inhibitors in melanoma patients: An Italian melanoma intergroup study
    Marconcini, R.
    Nuzzo, A.
    Manacorda, S.
    de Rosa, F.
    Fava, P.
    Astrua, C.
    Di Guardo, L. A.
    Raimondi, A.
    Stucci, S. L.
    Todisco, A.
    Cortellini, A.
    Bersanelli, M.
    Nigro, O.
    Palla, M.
    Palmieri, G.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 551 - 551
  • [7] Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
    Jackson, Natalie
    Rodgers, Theresa
    John, Ida
    Milton, Denai R.
    Haydu, Lauren Elaine
    Amaria, Rodabe Navroze
    Diab, Adi
    McQuade, Jennifer Leigh
    Patel, Sapna Pradyuman
    Tawbi, Hussein Abdul-Hassan
    Wong, Michael K. K.
    Davies, Michael A.
    Glitza, Isabella Claudia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.
    Zimmer, Lisa
    Dimitriou, Florentia
    Grover, Piyush
    Hassel, Jessica Cecile
    Erdmann, Michael
    Forschner, Andrea
    Johnson, Douglas Buckner
    Livingstone, Elisabeth
    Roesch, Alexander
    Ugurel, Selma
    Schulz, Carsten
    Berking, Carola
    Menzies, Alexander M.
    Long, Georgina V.
    Dummer, Reinhard
    Schadendorf, Dirk
    Albrecht, Lea Jessica
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors.
    Barcena, Edelyn
    VanAnh Trinh
    McIntyre, Susan E.
    Simien, Rinata
    Cain, Suzanne
    Diab, Adi
    Amaria, Rodabe Navroze
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Tawbi, Hussein Abdul-Hassan
    Davies, Michael A.
    Hwu, Wen-Jen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors
    Ramondetta, Alice
    Ribero, Simone
    Conti, Luca
    Fava, Paolo
    Marra, Elene
    Broganelli, Paolo
    Caliendo, Virginia
    Picciotto, Franco
    Guida, Michele
    Fierro, Maria Teresa
    Quaglino, Pietro
    [J]. ACTA DERMATO-VENEREOLOGICA, 2020, 100 (01)
12345